Literature DB >> 8435862

Inhibition of tumor formation from grafted murine papilloma cells by treatment of grafts with staurosporine, an inducer of squamous differentiation.

J E Strickland1, A A Dlugosz, H Hennings, S H Yuspa.   

Abstract

The microbial alkaloid staurosporine induces responses associated with protein kinase C activation, resulting in terminal differentiation in cultures of both normal and neoplastic mouse epidermal cells. As a cancer chemotherapy model, we treated grafts of mouse epidermal tumor cell lines 308 and SP-1 repeatedly with staurosporine. A dose-dependent inhibition of tumor formation, maximal at 0.025 nmol per treatment, was observed. Higher and lower doses were less effective, suggesting a specific target for staurosporine action. A single, low-dose treatment 2 weeks after grafting also markedly reduced tumor formation. Although in vitro evidence suggests that staurosporine-induced terminal squamous differentiation results from activation of protein kinase C, we found no inhibition of tumor growth in similar studies with the protein kinase C activator 12-O-tetradecanoylphorbol-13-acetate. These results indicate that staurosporine is an effective antitumor agent for eradicating squamous cell tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435862     DOI: 10.1093/carcin/14.2.205

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  2 in total

1.  Protein kinase Cdelta targets mitochondria, alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector.

Authors:  L Li; P S Lorenzo; K Bogi; P M Blumberg; S H Yuspa
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

2.  The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.

Authors:  Luowei Li; Suneet Shukla; Andrew Lee; Susan H Garfield; David J Maloney; Suresh V Ambudkar; Stuart H Yuspa
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.